* Inotek Pharmaceuticals announces top-line results of phase 2 fixed-dose combination trial of trabodenoson and provides corporate update

* Inotek Pharmaceuticals Corp - company evaluating strategic alternatives

* Inotek Pharmaceuticals Corp - trabodenoson FDC demonstrated moderate IOP reduction over latanoprost alone when dosed in morning

* Inotek Pharmaceuticals Corp - ‍has engaged Perella Weinberg Partners as a financial advisor to assist with strategic review process​

* Inotek Pharmaceuticals Corp - trabodenoson FDC had comparable efficacy dosed in afternoon, and at day 56 over latanoprost alone

* Inotek Pharmaceuticals - addition of trabodenoson to latanoprost offered no clinically meaningful advantage in eye pressure reduction over latanoprost alone

* Inotek - based on these results and results for phase 3 matrx-1 monotherapy trial, co evaluating future clinical potential of trabodenoson Source text for Eikon: Further company coverage: